An advisory board recommended Wednesday that Arkansass Medicaid program eliminate restrictions on the use of an expensive cystic fibrosis drug made by Vertex Pharmaceuticals Inc that are the subject of a legal battle in federal court  Members of the states Drug Utilization Review Board which is made up of Arkansas doctors and pharmacists recommended that the state adopt a revised set of criteria for prescribing the drug called Kalydeco that wouldnt require that patients seeking the drug first prove their health worsened
  